ELISA/assay

GENLISA™ SARS-CoV-2 (Covid-19) Delta/DeltaPlus Neutralizing Antibody (B.1.617.2, AY.1,AY.2) ELISA

KBVH430

1 x 96 wells

650 USD

GENLISA™ SARS-CoV-2 (Covid-19) Delta/DeltaPlus Neutralizing Antibody (B.1.617.2, AY.1,AY.2) ELISA

ELISA

1 x 96 wells

650 USD

ELISA for the Quantitative determination of neutralizing antibody to the SARS-CoV-2 Spike receptor binding domain (RBD) of Delta variant (India variant) in serum and plasma samples. One of the primaryWHO’s variants of concern, the delta coronavirus strain more was responsible for the second wave of the pandemic. Existing vaccines were only moderately effective against the variant. Therefore, the intended use of this Delta variant COVID-19 Neutralizing antibody ELISA is in the development of more efficacious vaccines and drug therapies. Detecting and quantifying neutralizing antibodies to SARS-CoV-2 offers important information in the evaluation of immune responses, development of vaccines and therapeutic drugs. As other Krishgen ELISA, these kits are based on monoclonal antibody detection for better sensitivity. Proprietary stabilizers and blockers for optimal signal:noise ratio, with specific antibodies allow for a robust ELISA. Features include a standard, ready-to-use protocol, and the option to run serum or plasma samples. The kit employs a blocking ELISA technique which mimics the virus neutralization process. Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions. The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 (ACE2) protein as a host receptor through their S1B domain. Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion. SARS-CoV-2 initiates an immune response, which leads to the production of antibodies. These neutralizing antibodies disable host receptor interactions and prevent viral entry into the cell. They, therefore, also provide protection against future infection from SARS-CoV-2, as they remain in the circulatory system for months to years post infection.

Human

The GENLISA™ ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum, plasma and cell culture supernatant as validated with the kit. The kit employs a blocking ELISA technique which mimics the virus neutralization process. SARS-CoV-2-neutralizing antibodies primarily target the trimeric spike (S) glycoproteins on the viral surface that mediate entry into host cells. The S protein has two functional subunits that mediate cell attachment (the S1 subunit, existing of four core domains S1A through S1D) and fusion of the viral and cellular membrane (the S2 subunit). Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions. The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin coverting enzyme 2 (ACE2) protein as a host receptor through their S1B domain. Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion. SARS-CoV-2 initiates an immune response, which leads to the production of antibodies. These neutralizing antibodies provide protection against future infection from SARS-CoV-2 (Variant B.1.617), as they remain in the circulatory system for months to years post infection. SARS-CoV-2 keeps evolving by continual mutation which enables the virus to evade vaccines and immune systems. Some of the mutations; the U.K. variant B.1.1.7, the Brazil variant P.1, the South Africa variant B.1.351 and the Indian variant B.1.617, may have allowed the virus to escape from neutralizing antibodies. The combination of L452R and T478K substitutions is present in B.1.617.2 (Delta) which was first reported in India. The mutations at K417N, L452R, T478K subsequently name to be known as Delta Plus. This Neutralizing Kit works on using Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD (K417N, L452R, T478K) Protein and a Neutralizing Antibody sensitive to the variant as a Standard/Calibrator to measure the effective inhibition %.

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

0 ng/ml - 2000 ng/ml

7.5 ng/ml

The method employs sandwich ELISA technique. The protein-protein interaction between HRP-RBD (K417N, L452R, T478K) and hACE2 can be blocked by neutralizing antibodies against SARS-CoV-2 RBD (K417N, L452R, T478K). Samples and controls are pipetted in a blank microtitre plate and incubated with HRP conjugated human SARSCoV-2 RBD (K417N, L452R, T478K) protein. The antibodies to SARS-CoV-2 (Variant B.1.617.2, AY.1, AY.2) present in the samples and controls bind to the SARS-CoV-2 RBD (K417N, L452R, T478K) protein to form a complex. This solution of bound and unbound antibodies to SARS-CoV-2 (Variant B.1.617.2) is then pipetted into human ACE2 coated microplate. After washing to remove the bound complex of Anti-SARS-CoV-2 and HRP conjugated SARS-CoV-2 RBD (K417N, L452R, T478K), the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionally to the amount of unbound Anti-SARS-CoV-2 (Covid-19) (Variant B.1.617.2, AY.1, AY.2) present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

SARS-CoV-2 Delta/DeltaPlus Neutralizing Antibodies

RUO

2-8 degrees C